AJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tello, R.
Right arrow Articles by Yucel, E. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tello, R.
Right arrow Articles by Yucel, E. K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?

Prediction Rule for Characterization of Hepatic Lesions Revealed on MR Imaging

Estimation of Malignancy

Richard Tello1, Helen M. Fenlon, Todd Gagliano, Victor L. S. deCarvalho and E. Kent Yucel

1 All authors: Department of Radiology, Boston University School of Medicine, Boston Medical Center, 88 E. Newton St., Atrium 2, Boston, MA 02118.



View larger version (17K):

[in a new window]
  		Fig. 1. —Receiver operating characteristic curve using T2, patient history, and gadopentetate dimeglumine enhancement character gives area under curve of 0.95.

 


View larger version (7K):

[in a new window]
  		Fig. 2. —Probability of malignancy of hepatic lesion as function of lesion's calculated T2.

 


View larger version (8K):

[in a new window]
  		Fig. 3. —Probability of malignancy of hepatic lesion as function of lesion's calculated T2 modified for patient with history of known primary or no known primary malignancy. Solid line = no known primary malignancy, dashed line = known primary malignancy.

 


View larger version (8K):

[in a new window]
  		Fig. 4. —Probability of malignancy of hepatic lesion as function of lesion's calculated T2 modified on basis of enhancement characteristics of contrast medium. Solid line = hemangiomalike enhancement, dashed line = no hemagiomalike enhancement.

 


View larger version (11K):

[in a new window]
  		Fig. 5. —Probability of malignancy of hepatic lesion as function of lesion's calculated T2 modified on basis of enhancement characteristics of contrast medium and patient history of prior malignancy status. Thin solid line = no primary malignancy and positive gadopentetate dimeglumine enhancement pattern, thick solid line = primary malignancy and negative gadopentetate dimeglumine enhancement pattern, dotted line = primary malignancy and positive gadopentetate dimeglumine enhancement pattern, dotted dashed line = no primary malignancy and negative gadopentetate dimeglumine enhancement pattern.

 

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Roentgen Ray Society.